

# Britta Weigelt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2359550/publications.pdf>

Version: 2024-02-01

244  
papers

21,060  
citations

9786

73  
h-index

11939

134  
g-index

250  
all docs

250  
docs citations

250  
times ranked

27181  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic characterization of small cell carcinomas of the uterine cervix. <i>Molecular Oncology</i> , 2022, 16, 833-845.	4.6	14
2	INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. <i>Cancer Discovery</i> , 2022, 12, 356-371.	9.4	68
3	The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features. <i>Modern Pathology</i> , 2022, 35, 193-201.	5.5	25
4	TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition. <i>Modern Pathology</i> , 2022, 35, 117-127.	5.5	16
5	Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome. <i>Clinical Cancer Research</i> , 2022, 28, 404-413.	7.0	13
6	Stromal <i>MED12</i> exon 2 mutations in complex fibroadenomas of the breast. <i>Journal of Clinical Pathology</i> , 2022, 75, 133-136.	2.0	2
7	Pathogenesis of Triple-Negative Breast Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2022, 17, 181-204.	22.4	132
8	<i>ATM</i> Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 761-770.	6.3	3
9	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
10	Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression. <i>Oncogene</i> , 2022, 41, 1835-1850.	5.9	9
11	Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. <i>Gynecologic Oncology</i> , 2022, 165, 239-247.	1.4	9
12	Same-Cell Co-Occurrence of RAS Hotspot and BRAF V600E Mutations in Treatment-Naive Colorectal Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100365.	3.0	1
13	Genomic landscape of endometrial carcinomas of no specific molecular profile. <i>Modern Pathology</i> , 2022, 35, 1269-1278.	5.5	33
14	Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas. <i>Modern Pathology</i> , 2022, 35, 962-971.	5.5	22
15	Recurrent <i>WWTR1</i> <i>S89W</i> mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix. <i>Journal of Pathology</i> , 2022, 257, 635-649.	4.5	2
16	Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers. <i>Npj Breast Cancer</i> , 2022, 8, 51.	5.2	9
17	MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4456-4465.	7.0	25
18	Evaluation of TERT mRNA expression using RNAscope®: A potential histopathologic diagnostic and prognostic tool. <i>Pathology Research and Practice</i> , 2022, 233, 153892.	2.3	2

#	ARTICLE	IF	CITATIONS
19	Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. <i>Nature Medicine</i> , 2022, 28, 946-957.	30.7	50
20	Fundamental immune oncogenicity trade-offs define driver mutation fitness. <i>Nature</i> , 2022, 606, 172-179.	27.8	23
21	Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2022-003430.	2.5	5
22	Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes. <i>Clinical Cancer Research</i> , 2022, 28, 4947-4956.	7.0	22
23	Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 266-273.	6.3	38
24	Problematic breast tumors reassessed in light of novel molecular data. <i>Modern Pathology</i> , 2021, 34, 38-47.	5.5	25
25	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. <i>Molecular Oncology</i> , 2021, 15, 1024-1039.	4.6	21
26	Whole exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 113-120.	3.0	4
27	Massively parallel sequencing analysis of 68 gastric-type cervical adenocarcinomas reveals mutations in cell cycle-related genes and potentially targetable mutations. <i>Modern Pathology</i> , 2021, 34, 1213-1225.	5.5	28
28	Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes. <i>Modern Pathology</i> , 2021, 34, 994-1007.	5.5	19
29	Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management. <i>Histopathology</i> , 2021, 78, 759-771.	2.9	13
30	Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 742-751.	6.3	98
31	Ultraviolet radiation drives mutations in a subset of mucosal melanomas. <i>Nature Communications</i> , 2021, 12, 259.	12.8	27
32	Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma: A Study of 79 Cases Using Whole Slide Imaging. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1132-1137.	2.5	11
33	Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4870-4882.	7.0	49
34	Clinicopathologic and Genomic Analysis of TP53-Mutated Endometrial Carcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 2613-2623.	7.0	49
35	Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies. <i>Scientific Reports</i> , 2021, 11, 3718.	3.3	18
36	Homologous recombination deficiency: how genomic signatures are generated. <i>Current Opinion in Genetics and Development</i> , 2021, 66, 93-100.	3.3	13

#	ARTICLE	IF	CITATIONS
37	Genomic Alterations in <i>PIK3CA</i> -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3K± Inhibitors. <i>Cancer Research</i> , 2021, 81, 2470-2480.	0.9	20
38	Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases. <i>Modern Pathology</i> , 2021, 34, 1570-1587.	5.5	57
39	TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 43.	5.2	16
40	Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development. <i>Npj Breast Cancer</i> , 2021, 7, 45.	5.2	7
41	Genetic characterisation of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma. <i>Histopathology</i> , 2021, 79, 176-186.	2.9	4
42	Independent real-world application of a clinical-grade automated prostate cancer detection system. <i>Journal of Pathology</i> , 2021, 254, 147-158.	4.5	57
43	Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 161, 535-544.	1.4	16
44	Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women. <i>Gynecologic Oncology</i> , 2021, 161, 545-552.	1.4	8
45	The genomic landscape of carcinomas with mucinous differentiation. <i>Scientific Reports</i> , 2021, 11, 9478.	3.3	9
46	Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARC) genes. <i>Modern Pathology</i> , 2021, 34, 1850-1859.	5.5	3
47	Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. <i>Npj Breast Cancer</i> , 2021, 7, 96.	5.2	38
48	Paired Tumor-Normal Sequencing Provides Insights into TP53-Related Cancer Spectrum in Li-Fraumeni Patients. <i>Journal of the National Cancer Institute</i> , 2021, , .	6.3	6
49	Pattern of disease and response to pembrolizumab in recurrent cervical cancer. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100831.	0.6	4
50	Diagnosis and management of an endometrial cancer patient with Cowden syndrome. <i>Gynecologic Oncology</i> , 2021, 163, 14-21.	1.4	6
51	Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies. <i>Npj Breast Cancer</i> , 2021, 7, 124.	5.2	7
52	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. <i>Lung Cancer</i> , 2021, 159, 66-73.	2.0	17
53	Spectrum of <i>BRAF</i> Mutations and Gene Rearrangements in Ovarian Serous Carcinoma. <i>JCO Precision Oncology</i> , 2021, 5, 1480-1492.	3.0	8
54	Ki67 Assessment in Breast Cancer: Are We There Yet?. <i>Journal of the National Cancer Institute</i> , 2021, 113, 797-798.	6.3	7

#	ARTICLE	IF	CITATIONS
55	Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation. <i>American Journal of Surgical Pathology</i> , 2021, 45, 77-92.	3.7	30
56	AKT1 E17K Inhibits Cancer Cell Migration by Abrogating $\beta$ -Catenin Signaling. <i>Molecular Cancer Research</i> , 2021, 19, 573-584.	3.4	10
57	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. <i>Cancer Discovery</i> , 2021, 11, 1212-1227.	9.4	139
58	Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. <i>Npj Breast Cancer</i> , 2021, 7, 135.	5.2	9
59	Diverse alterations associated with resistance to KRAS(G12C) inhibition. <i>Nature</i> , 2021, 599, 679-683.	27.8	183
60	Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors. <i>Npj Genomic Medicine</i> , 2021, 6, 99.	3.8	13
61	Pancreatoblastomas and mixed and pure acinar cell carcinomas share epigenetic signatures distinct from other neoplasms of the pancreas. <i>Modern Pathology</i> , 2021, , .	5.5	3
62	ESR1 hotspot mutations in endometrial stromal sarcoma with high-grade transformation and endocrine treatment. <i>Modern Pathology</i> , 2021, , .	5.5	5
63	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020, 112, 46-54.	6.3	97
64	Sclerosing epithelioid mesenchymal neoplasm of the pancreas—A proposed new entity. <i>Modern Pathology</i> , 2020, 33, 456-467.	5.5	10
65	Histologic spectrum of polymorphous adenocarcinoma of the salivary gland harbor genetic alterations affecting PRKD genes. <i>Modern Pathology</i> , 2020, 33, 65-73.	5.5	29
66	Evaluating Clonal Hematopoiesis in Tumor-Infiltrating Leukocytes in Breast Cancer and Secondary Hematologic Malignancies. <i>Journal of the National Cancer Institute</i> , 2020, 112, 107-110.	6.3	10
67	Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 738-745.	7.0	31
68	Immunohistochemical assessment of HRASQ61R mutations in breast adenomyoepitheliomas. <i>Histopathology</i> , 2020, 76, 865-874.	2.9	19
69	Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary. <i>Nature Communications</i> , 2020, 11, 44.	12.8	34
70	Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies. <i>Cancer Cytopathology</i> , 2020, 128, 133-145.	2.4	4
71	Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 156, 194-202.	1.4	35
72	Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity. <i>Modern Pathology</i> , 2020, 33, 1056-1064.	5.5	35

#	ARTICLE	IF	CITATIONS
73	Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. <i>Cell</i> , 2020, 183, 197-210.e32.	28.9	141
74	Acquisition of APOBEC Mutagenesis and Microsatellite Instability Signatures in the Development of Brain Metastases in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma. <i>JCO Precision Oncology</i> , 2020, 4, 1217-1223.	3.0	1
75	The genomic landscape of metastatic histologic special types of invasive breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 53.	5.2	27
76	Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers. <i>Scientific Reports</i> , 2020, 10, 17769.	3.3	35
77	Whole-exome analysis of metaplastic breast carcinomas with extensive osseous differentiation. <i>Histopathology</i> , 2020, 77, 321-326.	2.9	7
78	Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. <i>Nature Cancer</i> , 2020, 1, 1188-1203.	13.2	114
79	A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel) <i>Tj ETQq1 1 0.784314 rgBT /Over</i> 1627-1632.	2.5	16
80	FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. <i>Cancer Cell</i> , 2020, 38, 534-550.e9.	16.8	67
81	Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites. <i>Journal of Clinical Pathology</i> , 2020, , jclinpath-2020-207052.	2.0	5
82	Histologic Classification and Molecular Signature of Polymorphous Adenocarcinoma (PAC) and Cribriform Adenocarcinoma of Salivary Gland (CASG). <i>American Journal of Surgical Pathology</i> , 2020, 44, 545-552.	3.7	39
83	Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. <i>Nature Genetics</i> , 2020, 52, 582-593.	21.4	136
84	High-grade transformation of low-grade endometrial stromal sarcomas lacking YWHAE and BCOR genetic abnormalities. <i>Modern Pathology</i> , 2020, 33, 1861-1870.	5.5	26
85	Oncogenic properties and signaling basis of the PAX8-GLIS3 fusion gene. <i>International Journal of Cancer</i> , 2020, 147, 2253-2264.	5.1	10
86	BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 665-679.	3.0	29
87	Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes. <i>Npj Breast Cancer</i> , 2020, 6, 20.	5.2	25
88	Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary. <i>Modern Pathology</i> , 2020, 33, 1606-1617.	5.5	38
89	Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. <i>Modern Pathology</i> , 2020, 33, 2221-2232.	5.5	23
90	Mutant FOXL2C134W Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors. <i>Cancer Research</i> , 2020, 80, 3466-3479.	0.9	29

#	ARTICLE	IF	CITATIONS
91	A P53-Independent DNA Damage Response Suppresses Oncogenic Proliferation and Genome Instability. <i>Cell Reports</i> , 2020, 30, 1385-1399.e7.	6.4	29
92	ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. <i>Nature Genetics</i> , 2020, 52, 198-207.	21.4	140
93	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. <i>Nature Cancer</i> , 2020, 1, 382-393.	13.2	96
94	Endometrial Carcinomas with a Serous Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations. <i>American Journal of Surgical Pathology</i> , 2020, 44, 641-648.	3.7	34
95	Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 3682-3693.	7.0	42
96	HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers. <i>Cancer Discovery</i> , 2020, 10, 674-687.	9.4	149
97	The impact of poly ADP ribose polymerase (PARP) inhibitors on clonal hematopoiesis. <i>Journal of Clinical Oncology</i> , 2020, 38, 1513-1513.	1.6	16
98	Gastric-type adenocarcinoma of the cervix: Genomic drivers and clinical outcomes. <i>Journal of Clinical Oncology</i> , 2020, 38, 6030-6030.	1.6	1
99	Homologous recombination DNA repair defects in PALB2-associated breast cancers. <i>Npj Breast Cancer</i> , 2019, 5, 23.	5.2	39
100	How Did We Get There? The Progression from Ductal Carcinoma In Situ to Invasive Ductal Carcinoma. <i>Current Breast Cancer Reports</i> , 2019, 11, 175-184.	1.0	0
101	Molecular profiling and molecular classification of endometrioid ovarian carcinomas. <i>Gynecologic Oncology</i> , 2019, 154, 516-523.	1.4	62
102	Whole-exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast. <i>Histopathology</i> , 2019, 75, 931-937.	2.9	16
103	PAX8-GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid. <i>Modern Pathology</i> , 2019, 32, 1734-1743.	5.5	38
104	Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 2318-2330.	3.4	41
105	Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas. <i>Npj Breast Cancer</i> , 2019, 5, 6.	5.2	21
106	The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz027.	2.9	20
107	V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer. <i>Cancer Discovery</i> , 2019, 9, 1182-1191.	9.4	27
108	Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential. <i>Histopathology</i> , 2019, 75, 213-224.	2.9	46

#	ARTICLE	IF	CITATIONS
109	Genomic analysis of recurrences and high-grade forms of polymorphous adenocarcinoma. <i>Histopathology</i> , 2019, 75, 193-201.	2.9	10
110	Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma. <i>Histopathology</i> , 2019, 75, 139-145.	2.9	22
111	Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway. <i>Molecular Oncology</i> , 2019, 13, 1684-1692.	4.6	21
112	The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNP3-ALK rearrangement. <i>Human Pathology</i> , 2019, 88, 66-77.	2.0	38
113	Massively parallel sequencing analysis of benign melanocytic naevi. <i>Histopathology</i> , 2019, 75, 29-38.	2.9	12
114	Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers. <i>Scientific Reports</i> , 2019, 9, 16830.	3.3	29
115	Radiogenomics Analysis of Intratumor Heterogeneity in a Patient With High-Grade Serous Ovarian Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	3.0	10
116	FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 26823-26834.	7.1	103
117	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. <i>Nature Medicine</i> , 2019, 25, 1928-1937.	30.7	485
118	Endometrial Cancers in <i>BRCA1</i> or <i>BRCA2</i> Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	3.0	19
119	The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma. <i>Modern Pathology</i> , 2019, 32, 205-215.	5.5	22
120	Lobular Carcinomas <i>In Situ</i> Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 674-686.	7.0	44
121	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 39-45.	4.4	200
122	Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa. <i>Histopathology</i> , 2019, 74, 638-650.	2.9	11
123	Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. <i>Gynecologic Oncology</i> , 2019, 152, 11-19.	1.4	66
124	Recurrent <i>MED12</i> exon 2 mutations in benign breast fibroepithelial lesions in adolescents and young adults. <i>Journal of Clinical Pathology</i> , 2019, 72, 258-262.	2.0	22
125	The Genomic Landscape of Mucinous Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 737-741.	6.3	68
126	Genomic Applications in Gynecologic Malignancies. , 2019, , 445-469.		0



#	ARTICLE	IF	CITATIONS
127	Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. <i>Journal of Clinical Investigation</i> , 2019, 129, 4276-4289.	8.2	134
128	The molecular genetic make-up of male breast cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, 779-794.	3.1	27
129	The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1030-1034.	6.3	90
130	Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. <i>Cancer Research</i> , 2018, 78, 3112-3121.	0.9	57
131	Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting <i>IDH2</i> and <i>PIK3CA</i> : a validation cohort. <i>Histopathology</i> , 2018, 73, 339-344.	2.9	44
132	The value of cell-free DNA for molecular pathology. <i>Journal of Pathology</i> , 2018, 244, 616-627.	4.5	91
133	Triple-negative breast cancers – a panoply of cancer types. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 347-348.	27.6	45
134	Contralateral breast cancers: Independent cancers or metastases?. <i>International Journal of Cancer</i> , 2018, 142, 347-356.	5.1	37
135	Invasion in breast lesions: the role of the epithelial-stroma barrier. <i>Histopathology</i> , 2018, 72, 1075-1083.	2.9	25
136	Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 731-740.	2.5	71
137	<i>MYBL1</i> rearrangements and <i>MYB</i> amplification in breast adenoid cystic carcinomas lacking the <i>MYB</i> - <i>NFIB</i> fusion gene. <i>Journal of Pathology</i> , 2018, 244, 143-150.	4.5	74
138	Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity. <i>Cell Reports</i> , 2018, 25, 1446-1457.	6.4	76
139	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. <i>Oncotarget</i> , 2018, 9, 20617-20630.	1.8	36
140	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. <i>Cancer Cell</i> , 2018, 34, 893-905.e8.	16.8	307
141	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , 2018, 34, 427-438.e6.	16.8	633
142	Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. <i>Nature Communications</i> , 2018, 9, 3533.	12.8	92
143	Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. <i>Gynecologic Oncology</i> , 2018, 150, 127-135.	1.4	41
144	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5939-5947.	7.0	100

#	ARTICLE	IF	CITATIONS
145	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. <i>Nature Communications</i> , 2018, 9, 1816.	12.8	105
146	The clinical utility of prospective molecular characterization in advanced cervical and vulvovaginal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5531-5531.	1.6	0
147	Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications. <i>Current Breast Cancer Reports</i> , 2017, 9, 34-44.	1.0	11
148	Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast. <i>Molecular Oncology</i> , 2017, 11, 913-926.	4.6	11
149	Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples. <i>Nature Medicine</i> , 2017, 23, 376-385.	30.7	111
150	The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas. <i>Clinical Cancer Research</i> , 2017, 23, 3859-3870.	7.0	129
151	Generation of conditional oncogenic chromosomal translocations using CRISPR-Cas9 genomic editing and homology-directed repair. <i>Journal of Pathology</i> , 2017, 242, 102-112.	4.5	23
152	Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma. <i>Histopathology</i> , 2017, 71, 480-487.	2.9	2
153	HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5123-5134.	7.0	85
154	Myxoid fibroadenomas differ from conventional fibroadenomas: a hypothesis-generating study. <i>Histopathology</i> , 2017, 71, 626-634.	2.9	26
155	Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases. <i>Clinical Cancer Research</i> , 2017, 23, 4402-4415.	7.0	91
156	A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. <i>European Radiology</i> , 2017, 27, 3991-4001.	4.5	92
157	Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. <i>Journal of Pathology</i> , 2017, 242, 165-177.	4.5	43
158	The genetic landscape of breast carcinomas with neuroendocrine differentiation. <i>Journal of Pathology</i> , 2017, 241, 405-419.	4.5	52
159	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 244-254.	2.8	96
160	Reply to Rosen. <i>Modern Pathology</i> , 2017, 30, 1505-1506.	5.5	1
161	Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. <i>Nature Communications</i> , 2017, 8, 857.	12.8	182
162	Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways. <i>Npj Breast Cancer</i> , 2017, 3, 40.	5.2	52

#	ARTICLE	IF	CITATIONS
163	The genetic landscape of endometrial clear cell carcinomas. <i>Journal of Pathology</i> , 2017, 243, 230-241.	4.5	168
164	Mixed Mesonephric Adenocarcinoma and High-grade Neuroendocrine Carcinoma of the Uterine Cervix: Case Description of a Previously Unreported Entity With Insights Into Its Molecular Pathogenesis. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 76-89.	1.4	26
165	The Spectrum of Triple-Negative Breast Disease. <i>American Journal of Pathology</i> , 2017, 187, 2139-2151.	3.8	118
166	An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. <i>Nature Medicine</i> , 2017, 23, 929-937.	30.7	146
167	Diverse <i>BRCA1</i> and <i>BRCA2</i> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6708-6720.	7.0	194
168	Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast. <i>Npj Breast Cancer</i> , 2017, 3, 48.	5.2	63
169	De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. <i>Breast</i> , 2017, 34, S19-S26.	2.2	46
170	Leiomyoma with bizarre nuclei: a morphological, immunohistochemical and molecular analysis of 31 cases. <i>Modern Pathology</i> , 2017, 30, 1476-1488.	5.5	51
171	Prediction of Trastuzumab Benefit in HER2-Positive Breast Cancers: Is It in the Intrinsic Subtype?. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw218.	6.3	7
172	The molecular basis of breast cancer pathological phenotypes. <i>Journal of Pathology</i> , 2017, 241, 375-391.	4.5	86
173	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. <i>Modern Pathology</i> , 2017, 30, 69-84.	5.5	48
174	Clinicopathologic characteristics of endometrial carcinoma metastatic to the ovary compared to endometrial carcinoma with synchronous ovarian carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, e17105-e17105.	1.6	0
175	Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. <i>Oncotarget</i> , 2016, 7, 10051-10063.	1.8	247
176	Lack of <i>PRKD2</i> and <i>PRKD3</i> kinase domain somatic mutations in <i>PRKD1</i> wild-type classic polymorphous low-grade adenocarcinomas of the salivary gland. <i>Histopathology</i> , 2016, 68, 1055-1062.	2.9	23
177	Infiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profile. <i>Histopathology</i> , 2016, 68, 1030-1039.	2.9	31
178	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and <i>TERT</i> promoter hotspot mutations and <i>TERT</i> gene amplification as likely drivers of progression. <i>Journal of Pathology</i> , 2016, 238, 508-518.	4.5	102
179	Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring <i>TP53</i> somatic mutations. <i>Journal of Pathology</i> , 2016, 238, 677-688.	4.5	52
180	Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing. <i>Histopathology</i> , 2016, 68, 262-271.	2.9	22

#	ARTICLE	IF	CITATIONS
181	An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. <i>Breast Cancer Research</i> , 2016, 18, 121.	5.0	89
182	Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor. <i>Npj Breast Cancer</i> , 2016, 2, 16035.	5.2	28
183	<i>IDH2</i> Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. <i>Cancer Research</i> , 2016, 76, 7118-7129.	0.9	99
184	Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. <i>Modern Pathology</i> , 2016, 29, 476-488.	5.5	95
185	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4623-4633.	7.0	153
186	Risk Stratification and Intrinsic Subtype Classification of Breast Cancer: a Multi-Parameter Test to Rule Them All?. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw118.	6.3	9
187	Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. <i>Modern Pathology</i> , 2016, 29, 1292-1305.	5.5	68
188	Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management. <i>Histopathology</i> , 2016, 68, 45-56.	2.9	37
189	Phyllodes tumours of the breast: a consensus review. <i>Histopathology</i> , 2016, 68, 5-21.	2.9	329
190	AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients. <i>Npj Breast Cancer</i> , 2016, 2, 16033.	5.2	41
191	Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. <i>Npj Breast Cancer</i> , 2016, 2, 16036.	5.2	127
192	RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers. <i>European Journal of Cancer</i> , 2016, 64, 149-158.	2.8	8
193	Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors. <i>Cancer Research</i> , 2016, 76, 4525-4534.	0.9	33
194	Uterine adenosarcomas are mesenchymal neoplasms. <i>Journal of Pathology</i> , 2016, 238, 381-388.	4.5	94
195	TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 289-300.	1.4	89
196	Translating neoadjuvant therapy into survival benefits: one size does not fit all. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 566-579.	27.6	38
197	Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships. <i>Molecular Oncology</i> , 2016, 10, 360-370.	4.6	41
198	The Genomic Landscape of Male Breast Cancers. <i>Clinical Cancer Research</i> , 2016, 22, 4045-4056.	7.0	119

#	ARTICLE	IF	CITATIONS
199	DNA Copy Number Aberrations, and Human Papillomavirus Status in Penile Carcinoma. Clinico-Pathological Correlations and Potential Driver Genes. PLoS ONE, 2016, 11, e0146740.	2.5	19
200	Somatic mutations in leukocytes infiltrating primary breast cancers. Npj Breast Cancer, 2015, 1, 15005.	5.2	30
201	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. Journal of Pathology, 2015, 237, 166-178.	4.5	53
202	Are acinic cell carcinomas of the breast and salivary glands distinct diseases?. Histopathology, 2015, 67, 529-537.	2.9	37
203	<i>MED12</i> somatic mutations in fibroadenomas and phyllodes tumours of the breast. Histopathology, 2015, 67, 719-729.	2.9	78
204	Functional screening identifies <i>MCT4</i> as a key regulator of breast cancer cell metabolism and survival. Journal of Pathology, 2015, 237, 152-165.	4.5	73
205	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nature Communications, 2015, 6, 8839.	12.8	605
206	Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. Journal of the National Cancer Institute, 2015, 108, djv427.	6.3	164
207	Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion. Molecular Oncology, 2015, 9, 772-782.	4.6	32
208	Breast Cancer Genomics From Microarrays to Massively Parallel Sequencing: Paradigms and New Insights. Journal of the National Cancer Institute, 2015, 107, .	6.3	80
209	PIKING the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas. Gynecologic Oncology, 2015, 137, 321-328.	1.4	15
210	Genomic landscape of adenoid cystic carcinoma of the breast. Journal of Pathology, 2015, 237, 179-189.	4.5	133
211	In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nature Genetics, 2015, 47, 1212-1219.	21.4	139
212	Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. Genome Biology, 2015, 16, 107.	8.8	109
213	Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Science Translational Medicine, 2015, 7, 302ra133.	12.4	889
214	A survey of DICER1 hotspot mutations in ovarian and testicular sex cord-stromal tumors. Modern Pathology, 2015, 28, 1603-1612.	5.5	100
215	Metastatic breast carcinomas display genomic and transcriptomic heterogeneity. Modern Pathology, 2015, 28, 340-351.	5.5	80
216	Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Modern Pathology, 2015, 28, 505-514.	5.5	180

#	ARTICLE	IF	CITATIONS
217	Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure. <i>Oncotarget</i> , 2015, 6, 28327-28340.	1.8	24
218	Identifying somatic oncogenic mutations in leukocytes that infiltrate primary breast cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11000-11000.	1.6	0
219	Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival. <i>PLoS ONE</i> , 2014, 9, e114900.	2.5	77
220	A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. <i>Nature Genetics</i> , 2014, 46, 595-600.	21.4	152
221	Predictive Performance of Microarray Gene Signatures: Impact of Tumor Heterogeneity and Multiple Mechanisms of Drug Resistance. <i>Cancer Research</i> , 2014, 74, 2946-2961.	0.9	20
222	Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations. <i>Genome Biology</i> , 2014, 15, 484.	8.8	117
223	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 406-414.	10.7	703
224	Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. <i>Journal of Pathology</i> , 2014, 232, 553-565.	4.5	88
225	Metaplastic breast carcinoma: more than a special type. <i>Nature Reviews Cancer</i> , 2014, 14, 147-148.	28.4	69
226	Breast cancer intra-tumor heterogeneity. <i>Breast Cancer Research</i> , 2014, 16, 210.	5.0	256
227	Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. <i>Nature Genetics</i> , 2014, 46, 1166-1169.	21.4	188
228	Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast. <i>Molecular Oncology</i> , 2014, 8, 1588-1602.	4.6	49
229	Lobular Neoplasia. <i>Surgical Oncology Clinics of North America</i> , 2014, 23, 487-503.	1.5	27
230	Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing. <i>Molecular Oncology</i> , 2014, 8, 150-158.	4.6	37
231	Small cell carcinoma of the gynecologic tract: A multifaceted spectrum of lesions. <i>Gynecologic Oncology</i> , 2014, 134, 410-418.	1.4	79
232	Classification of endometrial carcinoma: more than two types. <i>Lancet Oncology</i> , The, 2014, 15, e268-e278.	10.7	479
233	Molecular Classification of Breast Cancer. <i>Surgical Pathology Clinics</i> , 2012, 5, 701-717.	1.7	10
234	Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. <i>Journal of Pathology</i> , 2012, 226, 84-96.	4.5	144

#	ARTICLE	IF	CITATIONS
235	Germline mutations in RAD51D confer susceptibility to ovarian cancer. <i>Nature Genetics</i> , 2011, 43, 879-882.	21.4	460
236	Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. <i>Journal of Pathology</i> , 2010, 220, 562-573.	4.5	185
237	Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. <i>Journal of Pathology</i> , 2010, 222, 282-298.	4.5	139
238	Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast. <i>Modern Pathology</i> , 2010, 23, 951-960.	5.5	56
239	Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 1938-1948.	27.0	3,233
240	Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 351-365.	2.8	80
241	Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 273-280.	2.5	208
242	Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. <i>Modern Pathology</i> , 2009, 22, 1401-1414.	5.5	110
243	Histological and molecular types of breast cancer: is there a unifying taxonomy?. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 718-730.	27.6	353
244	Genomic determinants of early recurrences in low-stage low-grade endometrioid endometrial carcinoma. <i>Journal of the National Cancer Institute</i> , 0, , .	6.3	1